Download Files:
Nilotinib
$66 – $158
Products Details
Product Description
– Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
Web ID
– HY-10159
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C28H22F3N7O
Citations
– ACS Chem Biol. 2016 Apr 15;11(4):992-1000.|Biomaterials. 16 September 2022.|Biomed Chromatogr. 2019 Dec;33(12):e4674.|Biomolecules. 2022 Jun 11;12(6):819.|Br J Cancer. 2021 Nov 24.|Breast Cancer Res. 2023 May 5;25(1):51.|Cancer Biol Ther. 2019;20(6):877-885.|Cancer Med. 2016 Nov;5(11):3223-3234.|Cell Death Dis. 2021 Sep 25;12(10):875.|Cell Syst. 2018 Apr 25;6(4):424-443.e7.|Diseases. 2023 Oct 23;11(4):147.|Eur J Pharmacol. 2021 Feb 10;173944.|Glia. 2022 Feb 13.|Harvard Medical School LINCS LIBRARY|Int J Mass Spectrom. 442 (2019) 44-50.|J Pharm Sci. 2017 Sep;106(9):2632-2641.|Leuk Lymphoma. 2015;56(8):2416-23. |Oncotarget. 2018 Apr 24;9(31):22158-22183. |Patent. US20190084960A1|Patent. US20210299273A1.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|Stem Cell Reports. 2019 May 14;12(5):996-1006. |Target Oncol. 2020 Oct;15(5):659-671.|Technical University of Munich. 24.01.2018.|Toxicol Lett. 2022 Jun 6;S0378-4274(22)00117-5.|Xenobiotica. 2018 Oct;48(10):1059-1071. |bioRxiv. January 25, 2022.|Drug Metab Pharmacokinet. 2020 Feb;35(1):102-110.
References
– [1]Dervis Hakim G, et al. Mucosal healing effect of nilotinib in indomethacin-induced enterocolitis: A rat model. World J Gastroenterol. 2015 Nov 28;21(44):12576-85.|[2]Weisberg E, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1;109(5):2112-20.|[3]Sako H, et al. Antitumor effect of the tyrosine kinase inhibitor Nilotinib on gastrointestinal stromal tumor (GIST) and Imatinib-resistant GIST cells. PLoS One. 2014 Sep 15;9(9):e107613.|[4]Fujita KI, et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites. J Pharm Sci. 2017 Sep;106(9):2632-2641.|[5]Meirson T, et al. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget. 2018 Apr 24;9(31):22158-22183.
CAS Number
– 641571-10-0
Molecular Weight
– 529.52
Compound Purity
– 99.94
SMILES
– O=C(NC1=CC(C(F)(F)F)=CC(N2C=NC(C)=C2)=C1)C3=CC=C(C)C(NC4=NC=CC(C5=CC=CN=C5)=N4)=C3
Clinical Information
– Launched
Research Area
– Cancer
Solubility
– DMSO : 12.5 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Autophagy;Bcr-Abl
Pathway
– Autophagy;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
